[go: up one dir, main page]

WO2012138102A3 - Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 - Google Patents

Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2012138102A3
WO2012138102A3 PCT/KR2012/002496 KR2012002496W WO2012138102A3 WO 2012138102 A3 WO2012138102 A3 WO 2012138102A3 KR 2012002496 W KR2012002496 W KR 2012002496W WO 2012138102 A3 WO2012138102 A3 WO 2012138102A3
Authority
WO
WIPO (PCT)
Prior art keywords
human antibodies
dlk1
fragments
pharmaceutical composition
extracellular water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002496
Other languages
English (en)
French (fr)
Other versions
WO2012138102A2 (ko
Inventor
박영우
조기원
이동희
윤선하
손명호
김경진
김동진
이유라
박찬웅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120001457A external-priority patent/KR101438265B1/ko
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2012138102A2 publication Critical patent/WO2012138102A2/ko
Publication of WO2012138102A3 publication Critical patent/WO2012138102A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 DLK1의 세포 외 영역 수용성 도메인에 특이적으로 결합하는 인간 항체 또는 이의 항원결합 부위를 포함하는 단편, 상기 인간 항체 또는 이의 단편을 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 재조합 벡터, 상기 재조합 벡터로 형질전환된 형질전환체, 상기 인간 항체 또는 이의 단편을 제조하는 방법, 상기 인간 항체 또는 이의 단편을 포함하는 질환의 예방 또는 치료용 약학적 조성물 및 진단 키트에 관한 것이다. 본 발명의 DLK1의 세포 외 영역 수용성 도메인에 특이적으로 결합하는 인간 항체 또는 이의 항원결합부위를 단편은 항암효과를 나타낼 뿐만 아니라, DLK1의 세포 외 영역 수용성 도메인의 액티빈 수용체 타입 2B에 대한 결합력을 현저히 상승시키는바, 암을 포함하여 ACVR2B의 신호 전달 기작과 관련된 대사질환, 면역계 질환 또는 간 질환의 예방 또는 치료에 유용하게 사용할 수 있다.
PCT/KR2012/002496 2011-04-04 2012-04-03 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 Ceased WO2012138102A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110030871 2011-04-04
KR10-2011-0030871 2011-04-04
KR1020120001457A KR101438265B1 (ko) 2011-04-04 2012-01-05 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
KR10-2012-0001457 2012-01-05

Publications (2)

Publication Number Publication Date
WO2012138102A2 WO2012138102A2 (ko) 2012-10-11
WO2012138102A3 true WO2012138102A3 (ko) 2013-01-10

Family

ID=46969663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002496 Ceased WO2012138102A2 (ko) 2011-04-04 2012-04-03 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물

Country Status (1)

Country Link
WO (1) WO2012138102A2 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006249A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
KR102125032B1 (ko) * 2017-09-08 2020-06-19 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
CN112601555A (zh) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 与抗cd19抗体药物结合物相关的组合物和方法
EP3657176A1 (en) * 2018-11-23 2020-05-27 Syddansk Universitet Dlk1 as a predictive marker for insulin resistance and/or type 2 diabetes and/or metabolic syndrome
KR102503143B1 (ko) * 2019-03-06 2023-02-24 주식회사 레고켐 바이오사이언스 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
MX2021010453A (es) * 2019-03-06 2021-09-21 Legochem Biosciences Inc Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1702982A1 (en) * 2003-11-28 2006-09-20 Kanagawa Academy Of Science And Technology Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer
EP1394263B1 (en) * 2001-05-16 2008-10-08 Kanagawa Academy Of Science And Technology Methods for detection and separation of undifferentiated hepatic cells using dlk
KR20090088893A (ko) * 2006-11-10 2009-08-20 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
KR100982170B1 (ko) * 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394263B1 (en) * 2001-05-16 2008-10-08 Kanagawa Academy Of Science And Technology Methods for detection and separation of undifferentiated hepatic cells using dlk
EP1702982A1 (en) * 2003-11-28 2006-09-20 Kanagawa Academy Of Science And Technology Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer
KR20090088893A (ko) * 2006-11-10 2009-08-20 가부시키가이샤 리부텍쿠 ｉｎ ｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
KR100982170B1 (ko) * 2010-03-16 2010-09-15 한국생명공학연구원 ＤＬＫ１―Ｆｃ 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물

Also Published As

Publication number Publication date
WO2012138102A2 (ko) 2012-10-11

Similar Documents

Publication Publication Date Title
WO2012138102A3 (ko) Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
WO2011025964A3 (en) Therapeutic dll4 binding proteins
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
HK1250513A1 (zh) 抗ox40抗体及其使用方法
MY200162A (en) Anti-gitr antibodies and uses thereof
JO3097B1 (ar) الأجسام المضادة c-Met
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
MX369148B (es) Agentes de unión kir3dl2.
WO2015073580A8 (en) Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
WO2012162243A3 (en) Anti-cgrp compositions and use thereof
WO2012106556A3 (en) Methods and compositons relating to inhibition of igf-1r
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
WO2014062659A3 (en) Methods of treating ocular diseases
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
PH12012501884B1 (en) Humanized il-25 antibodies
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
TN2015000277A1 (en) Bmp-6 antibodies
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
PH12014502582A1 (en) Compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12768656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12768656

Country of ref document: EP

Kind code of ref document: A2